Tilman Schneider-Hohendorf

Department of Neurology with Institute of Translational Neurology, University Hospital Münster

Affiliated withUniversity Hospital Münster

Research Area

Biography

Tilman Schneider-Hohendorf has not added Biography.
If you are Tilman Schneider-Hohendorf and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 6	2017

Other Publications

Article	Year
Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis. PloS one\| PubMed ID: 21085578	2010
Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis. European journal of immunology\| PubMed ID: 21108477	2010
Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. Journal of autoimmunity\| PubMed ID: 21216565	2011
Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels. Biochimica et biophysica acta\| PubMed ID: 21575593	2011
Immunological and clinical consequences of treating a patient with natalizumab. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 21908480	2012
L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology\| PubMed ID: 23925765	2013
Specific loss of cellular L-selectin on CD4+ T cells is associated with PML development during HIV infection. AIDS (London, England)\| PubMed ID: 24445368	2014
Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Annals of neurology\| PubMed ID: 24771567	2014
VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. The Journal of experimental medicine\| PubMed ID: 25135296	2014
Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis. International immunology\| PubMed ID: 25326459	2015
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). BMC neurology\| PubMed ID: 26099927	2015
Trafficking of lymphocytes into the CNS. Oncotarget\| PubMed ID: 26255669	2015
Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. Annals of clinical and translational neurology\| PubMed ID: 26401512	2015
PML risk stratification using anti-JCV antibody index and L-selectin. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 26432858	2016
CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro-oncology\| PubMed ID: 26578623	2016
Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurology(R) neuroimmunology & neuroinflammation\| PubMed ID: 26848486	2016
CD8(+) T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing. Nature communications\| PubMed ID: 27040081	2016
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 27162345	2016
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology\| PubMed ID: 27572431	2016
CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology\| PubMed ID: 27815407	2016
Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification. Neurology\| PubMed ID: 28228564	2017